After the second vaccination, AstraZeneca provokes a more extensive cellular response in the elderly

After the second vaccination, AstraZeneca provokes a more extensive cellular response in the elderly

a Pre-prints with The Lancet An outstanding English study comparing antibody production to coronavirus vaccines has been published by Pfizer / BioNTech and AstraZeneca in the elderly on Szabolux Dobson Pharmacist, licensing expert who deals with vaccines In your Facebook group.

The study compared rates of adaptive immune response in 165 people, ages 80 to 96, five weeks after the first dose of the two vaccines. The different vaccine types are also compared here because Pfizer is based on mRNA and AstraZeneca is an adenovirus vector vaccine.

According to the study, the antibody response to the spike protein from the Pfizer-BioNTech vaccine was detected in 93 percent of those vaccinated and 87 percent in the case of the AstraZeneca vaccine. However, Dobson writes, “The high protein T-cell immune response was observed in 12% of those vaccinated with Pfizer / BioNTech, compared to 31% of those vaccinated with AstraZeneca, and the average response to AstraZeneca was three times that of Pfizer. / BioNTech vaccine. In previous infections, immune responses were significantly stronger.

It is not yet known exactly what this means in practice, but older adults appear to have the same antibody production after the two vaccines as the two vaccines, but after the second dose of AstraZeneca, the cellular immune response is more extensive.

READ  Seven Dutch parties also run an unconstitutional program in next week's parliamentary elections

Leave a Reply

Your email address will not be published. Required fields are marked *